Literature DB >> 8871795

A controlled trial of cognitive-behavioural treatment of hypochondriasis.

H M Warwick1, D M Clark, A M Cobb, P M Salkovskis.   

Abstract

BACKGROUND: Hypochondriasis is a distressing disorder for which there is no adequate established treatment. This study evaluates the effect of cognitive-behavioural treatment of hypochondriasis, compared with a waiting list control.
METHOD: Thirty-two patients were randomly assigned to either cognitive-behavioural therapy or a no treatment waiting list control. Cognitive-behavioural treatment consisted of 16 individual treatment sessions over a four-month period. The waiting list control lasted for four months and was followed by 16 sessions of cognitive-behavioural treatment. Assessments were made before allocation and after treatment or waiting list control. Patients who had cognitive-behavioural treatment were reassessed three months after completion of treatment.
RESULTS: Paired comparisons on post-treatment/wait scores indicated that the cognitive-behavioural group showed significantly greater improvements than the waiting list on all but one patient rating, all therapist ratings and all assessor ratings. After three months the benefits of therapy were maintained.
CONCLUSIONS: Cognitive-behavioural treatment is an effective therapy for hypochondriasis. Implications of the study are discussed.

Entities:  

Mesh:

Year:  1996        PMID: 8871795     DOI: 10.1192/bjp.169.2.189

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  13 in total

Review 1.  Who is suitable for cognitive behavioural therapy?

Authors:  P Blenkiron
Journal:  J R Soc Med       Date:  1999-05       Impact factor: 5.344

Review 2.  Health anxiety: current perspectives and future directions.

Authors:  Gordon J G Asmundson; Jonathon S Abramowitz; Ashley A Richter; Margaret Whedon
Journal:  Curr Psychiatry Rep       Date:  2010-08       Impact factor: 5.285

3.  Abdominal pain of psychotic origin.

Authors:  Z Khan; J Stern; A Forbes
Journal:  J R Soc Med       Date:  1997-04       Impact factor: 5.344

4.  Thought-shape fusion in anorexia and bulimia nervosa: a comparative experimental study.

Authors:  Myrsini Kostopoulou; Eleftheria Varsou; Anastassios Stalikas
Journal:  Eat Weight Disord       Date:  2013-07-24       Impact factor: 4.652

5.  Sudden gains in internet-based cognitive behaviour therapy for severe health anxiety.

Authors:  Erik Hedman; Mats Lekander; Brjánn Ljótsson; Nils Lindefors; Christian Rück; Stefan G Hofmann; Erik Andersson; Gerhard Andersson; Stefan M Schulz
Journal:  Behav Res Ther       Date:  2014-01-11

Review 6.  Treating patients with medically unexplained symptoms in primary care.

Authors:  Robert C Smith; Catherine Lein; Clare Collins; Judith S Lyles; Barbara Given; Francesca C Dwamena; John Coffey; AnneMarie Hodges; Joseph C Gardiner; John Goddeeris; C William Given
Journal:  J Gen Intern Med       Date:  2003-06       Impact factor: 5.128

7.  Thought-Shape Fusion in bulimia nervosa: an experimental investigation.

Authors:  M Kostopoulou; E Varsou; A Stalikas
Journal:  Eat Weight Disord       Date:  2010-11-23       Impact factor: 3.008

8.  Protocol investigating the clinical outcomes and cost-effectiveness of cognitive-behavioural therapy delivered remotely for unscheduled care users with health anxiety: randomised controlled trial.

Authors:  Shireen Patel; Sam Malins; Boliang Guo; Marilyn James; Joe Kai; Catherine Kaylor-Hughes; Emma Rowley; Jayne Simpson; David Smart; Michelle Stubley; Helen Tyrer; Richard Morriss
Journal:  BJPsych Open       Date:  2016-02-25

9.  Pilot trial of a therapist-supported internet-delivered cognitive behavioural therapy program for health anxiety.

Authors:  Jill M Newby; Alison E J Mahoney; Elizabeth C Mason; Jessica Smith; Shivani Uppal; Gavin Andrews
Journal:  Internet Interv       Date:  2016-10-02

10.  Mediators in internet-based cognitive behavior therapy for severe health anxiety.

Authors:  Erik Hedman; Erik Andersson; Gerhard Andersson; Nils Lindefors; Mats Lekander; Christian Rück; Brjánn Ljótsson
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.